Back to top
more

IDEAYA Biosciences (IDYA)

(Delayed Data from NSDQ)

$40.32 USD

40.32
596,585

-0.18 (-0.44%)

Updated May 20, 2024 04:00 PM ET

After-Market: $40.36 +0.04 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IDYA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

IDEAYA Biosciences, Inc. [IDYA]

Reports for Purchase

Showing records 101 - 120 ( 167 total )

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

03/24/2021

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

03/24/2021

Company Report

Pages: 6

Q4 Financials; Broad Progress Across Pipeline; Investor Day Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

03/23/2021

Company Report

Pages: 6

4Q20 - Momentum Builds Ahead of Two Key Readouts During 2021

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

03/23/2021

Company Report

Pages: 8

4Q20 Results; First Patient Expected to be Dosed With IDE397 This Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

03/15/2021

Company Report

Pages: 7

Investor Meeting Takeaways - Focus on MAT2Ai IDE397 Program

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

03/15/2021

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

03/11/2021

Daily Note

Pages: 3

Presentations Announced for 2021 Annual Meeting of AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

03/11/2021

Industry Report

Pages: 3

Our Covered Companies Will Present at AACR

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

03/03/2021

Daily Note

Pages: 4

Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

02/23/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

02/22/2021

Company Report

Pages: 5

Ideaya to Host its Inaugural Synthetic Lethality Investor Day- April 20th

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

02/19/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

02/18/2021

Company Report

Pages: 6

Industry Veteran Susan Kelley, MD Joins Ideaya''s Board of Directors

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

02/09/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

02/08/2021

Daily Note

Pages: 3

FDA Clears IND to Launch Phase 1 Trial to Evaluate IDE397

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

02/08/2021

Company Report

Pages: 5

Maurer to Help Accelerate Development of Phase 1-Ready SL Program IDE397

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

01/21/2021

Company Report

Pages: 8

MAT2A Inhibitor IND Submission; Preclinical Data Points toLarge Opportunity

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

01/12/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

01/11/2021

Company Report

Pages: 6

IND for First Synthetic Lethality Program Submitted - Data During 2021

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

01/11/2021

Daily Note

Pages: 3

IND Submitted for MAT2A Development Candidate IDE397

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party